Rheumatoid ArthritisPhase 2NCT02983227
A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350
A Phase 2 study testing GDC-0853 in people with Rheumatoid Arthritis, run by Genentech, Inc. at 104 sites in 10 countries.
Trial summary
A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Read more about this study
- Who is it for?
- Ages 18 to 76 years
- Conditions the study is for
- Rheumatoid Arthritis
- What is being tested?
- GDC-0853
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 496 participants
- Where
- 104 sitesin 10 countries
- Study dates
- 30 Nov 2016to 17 Jul 2019
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 76 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Completion of treatment as specified in Study GA29350, including completion of the Day 84 study visit assessments
- Acceptable safety and tolerability during Study GA29350 as determined by the investigator or Medical Monitor
- Have not received any prohibited medications in Study GA29350
- While taking methotrexate, must be willing to receive oral folic acid (at least 5 milligrams per week [mg/week])
- If receiving oral corticosteroids (less than or equal to [</=] 10 milligrams per day [mg/day] prednisone or equivalent) and/or non-steroidal anti-inflammatory drugs, doses have remained stable for the duration of Study GA29350
Who cannot join
- Met protocol defined treatment stopping criteria during Study GA29350
- Treatment with any investigational agent (i.e., other than study drug) or live/attenuated vaccine or any other prohibited medication during Study GA29350 or since the last administration of study drug in Study GA29350
- In the opinion of the investigator, any new (since initially enrolling in the Phase II Study GA29350), significant, uncontrolled comorbidity that would increase the risk to the participant in Study GA30067
- Pregnant or lactating, or intending to become pregnant during the study
- Participants who experienced a de novo or reactivated serious viral infection such as hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) during the Phase II Study GA29350
- Any major episode of infection requiring hospitalization or treatment with intravenous antibiotics during the Phase II Study GA29350
Show all 9Show fewer
- Participants who developed a malignancy during the Phase II Study GA29350
- 12-lead electrocardiogram (ECG) on Day 84 in Study GA29350 that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
- Current treatment with medications that are well known to prolong the QT interval
Trial locations and contacts
104 sites in 10 countries.
104 sites in 10 countries
Ukraine21 sites
Railway Transp DCH of HealthCenter Branch of PJSC Ukr Railway Dept of Rheumatology
Dnipro, Tavria Okruha, 49008
Regional CH Dep of Rheumatology SHEI Ivano-Frankivsk NMU
Ivano-Frankivsk, KIEV Governorate, 76008
CI of Healthcare Kharkiv CCH #8 Dept of Therapy Kharkiv MA of PGE of MOHU
Kharkiv, Kharkiv Governorate, 61176
GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine
Kharkiv, 61039
MI of Healthcare Kyiv RCH P.L. Shupyk NMA of PGE
Kyiv, Chernihiv Governorate, 01601
SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU
Kyiv, KIEV Governorate, 03680
Medical Center of Revmotsentr LLC
Kyiv, KIEV Governorate, 04070
Medical Center of Limited Liability Company Medical Clinic Blagomed
Kyiv, KIEV Governorate, 1023
Med Center of International Institute of Clinical Trials LLC; Medical Center "OK!Clinic+"
Kyiv, KIEV Governorate, 2091
CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv
Kyiv, 02232
CI Lutsk CCH Volyn Regional Center of Cardiovascular Pathology and Thrombolysis
Lutsk, Volhynian Governorate, 43024
Lviv Regional Clinical Hospital Dept of Rehmuaatology D. Halytskyi Lviv NMU
Lviv, KIEV Governorate, 79010
CH of State Border Service of Ukraine (Military Base 2522); Dept of Therapy, D.Halytskyi Lviv NMU
Lviv, KIEV Governorate, 79014
M.V. Sklifosovsky Poltava RCH Dept of Rheumatology HSEIU UMSA
Poltava, 36011
CI of TRC
Ternopil, Kherson Governorate, 46002
A.Novak Transcarpathian Regional Clinical Hospital
Uzhhorod, KIEV Governorate, 88018
National Pirogov Memorial Medical University
Vinnytsia, Podolia Governorate, 21018
City Clinical Hospital #9 Dept of Therapy SI Zaporizhzhia MA of PGE of MoHU
Zaporizhzhya, Tavria Okruha, 69065
CI City Hospital #1
Zaporizhzhya, Tavria Okruha, 69104
CI City Hospital #7
Zaporizhzhya, 69118
CI Zaporizhzhia Regional Clinical Hospital of ZRC
Zaporizhzhya, 69600
Russia19 sites
SMMIH "Chelyabinsk Regional Clinical Hospital"
Chelyabinsk, Voronez, 454076
SAHI of Kem. "Regional Clinical Hospital for War Veterans"
Kemerovo, 650000
OOO Family Polyclinic
Korolev, Moscow Region, 141060
Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova
Moscow, Moscow Oblast, 115522
SBIH of Moscow "City Clinical Hospital # 1 n. a. N. I. Pirogov"
Moscow, Moscow Oblast, 119049
Practical Medicine
Moscow, 115404
Limited Liability Company "Centre of Medical Common Practice"
Novosibirsk, 630091
Ultramed
Omsk, 644024
SPb SBIH "Clinical Rheumatological Hospital # 25"
Saint Petersburg, Sankt-Peterburg, 190068
Sanavita LLC
Saint Petersburg, Sankt-Peterburg, 195257
LLC Medical Sanitary Unit
Saint Petersburg, Sankt-Peterburg, 196066
SEIHPE Saratov State Medical University n.a. V.I. Razumovskiy
Saratov, 410012
NIH "Departmental Hospital on Station Smolensk of OJSC "Russian Railways"
Smolensk, 214025
Siberian State Medical University
Tomsk, 634050
SHI Ulyanovsk Reg Clinical Hospital
Ulyanovsk, 432063
Territorial Clinical Hospital #2
Vladivostok, 690035
SBHI of Yaroslavl Region Clinical Hospital #3
Yaroslavl, Volgograd Oblast, 150051
SBIH of Yaroslavl region " Regional Clinical Hospital "; Therapy
Yaroslavl, Yaroslavl Oblast, 150062
Center of Family Medicine LC
Yekaterinburg, Sankt-Peterburg, 620043
United States11 sites
RASF-Clinical Research Center
Boca Raton, Florida, 33486
Clinical Research of West Florida
Clearwater, Florida, 33765
Medvin Clinical Research
Covina, California, 91723
Metroplex Clinical Research Centre
Dallas, Texas, 75231
Baylor Research Inst.
Dallas, Texas, 75246
TriWest Research Associates, LLC
El Cajon, California, 92020
Saint Jude Heritage Medical Grp
Fullerton, California, 92835
Arizona Arthritis & Rheumatology Associates, P.C.
Glendale, Arizona, 85306
Medication Management
Greensboro, North Carolina, 27408
Accurate Clinical Research
Houston, Texas, 77089
Oregon Health & Science Uni
Portland, Oregon, 97239
Argentina11 sites
Instituto de Investigaciones Clinicas-Mar del Plata
Buenos Aires, B7600FZN
APRILLUS
Buenos Aires, C1194AAO
Instituto centenario
Buenos Aires, C1204AAD
Centro de Investigacion en Enfermedades Reumaticas CIER
Ciudad Autonoma Buenos Aires, C1055AAF
Expertia S.A- Mautalen Salud e Investigación
Ciudad Autonoma Buenos Aires, C1128AAE
CCBR - Buenos Aires - AR; AxisMed SRL
Ciudad Autonoma Buenos Aires, C1430CKE
ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas
Córdoba, X5000BNB
Centro de Investigaciones Medicas Mar Del Plata
Mar del Plata, B7600DHK
Instituto de Investigaciones Clinicas
Rosario, S2000CVD
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
San Juan, 5400
Centro Medico Privado de Reumatologia; Reumathology
San Miguel, T4000AXL
Bulgaria9 sites
MHAT "Eurohospital" - Plovdiv, OOD; Internal Department
Plovdiv, 4002
UMHAT "Kaspela", EOOD
Plovdiv, 4002
Medizinski Zentrar-1-Sevlievo EOOD
Sevlievo, 5400
MHAT "Hadzhi Dimitar", OOD
Sliven, 8800
Medical Center Excelsior OOD
Sofia, 1000
NMTH "Tsar Boris III"
Sofia, 1233
DCC "Alexandrovska", EOOD; Clinic of Neurology
Sofia, 1431
MC "Synexus - Sofia", EOOD
Sofia, 1784
UMHAT "SofiaMed", OOD; Department of Neurology
Sofia, 1797
Mexico9 sites
Consultorio Medico en Fundacion el Hospitalito de morelos A.C.
Cuernavaca, Morelos, 62170
Consultorio Particular del Dr. Miguel Cortes Hernandez
Cuernavaca, 62290
Centro de Investigacion de Tratam Innovadores de Sin SC
Culiacán, 80230
Centro de Investigacion en Reumatologia
Mérida, Yucatán, 97070
Centro de Investigacion en Enfermedades Reumaticas y Osteoporosis
Mexicali, 21100
Centro de Investigacion Clínica GRAMEL S.C
México, 03720
Policlinica Medica de Queretaro S.C.
Querétaro, 76000
Clinical Research Institute
Tlalnepantla, 54055
Unidad de Enfermedades Reumaticas y Cronicodegenerativas
Torreón, 27000
Poland9 sites
NZOZ ZDROWIE Osteo-Medic
Bialystok, 15-351
Szpital Uniwersytecki; nr 2 im. Dr J. Biziela
Bydgoszcz, 85-168
Centrum Medyczne Pratia Katowice I
Katowice, 40-081
CCBR - Lodz - PL
Lodz, 90-368
ETYKA Osrodek Badan Kliniczynch
Olsztyn, 10-117
Ai Centrum Medyczne Sp. Z O.O Sp.K.
Poznan, 61-113
Medycyna Kliniczna
Warsaw, 00-660
Centrum Medyczne AMED
Warsaw, 03-291
KO-MED Centra Kliniczne Zamosc
Zamość, 22400
Brazil7 sites
CAEP - Centro Avancado de Estudos e Pesquisas Ltda.
Campinas, São Paulo, 13087-567
Centro de Estudos em Terapias Inovadoras - CETI
Curtiba, Paraná, 80030-110
CIP - Centro Internacional de Pesquisa X; Pesquisa Clinica
Goiânia, Goiás, 74110-120
CMiP - Centro Mineiro de Pesquisa*X*
Juiz de Fora, Minas Gerais, 36010-570
LMK Serviços Médicos S/S
Porto Alegre, Rio Grande do Sul, 90480-000
CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda.
Rio de Janeiro, Rio de Janeiro, 21941-913
IMA Brasil - Instituto de Medicina Avancada
São Paulo, São Paulo, 05437-000
Serbia5 sites
Institute of Rheumatology
Belgrade, 11000
Clinical Center Kragujevac
Kragujevac, 34000
Institute of Treatment and Rehabilitation "Niska Banja"
Niška Banja, 18205
Special hospital for rheumatic diseases Novi Sad
Novi Sad, 21000
General Hospital "Dr Laza K. Lazarevic" Sabac
Šabac, 15000
Colombia3 sites
Centro de Investigacion Medico Asistencial S.A.S
Barranquilla, 80020
Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM
Bogotá, 110221
Riesgo de Fractura S.A.
Bogotá, 110221
About this study
Official title: A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis
A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Eligible participants from Study GA29350 who elect to participate will receive treatment with GDC-0853 twice daily (BID) in an open-label fashion for 52 weeks, followed by a safety follow-up period of 8 weeks.
- Conditions
- Rheumatoid Arthritis
- Being tested
- GDC-0853
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GDC-0853Drug
Also called RO7010939
GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above.
| Study group | Role | What they receive |
|---|---|---|
| GDC-0853 (200mg BID) Cohort 1 | Experimental | Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo. Receives: Drug: GDC-0853 |
| GDC-0853 (200mg BID) Cohort 2 | Experimental | Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo. Receives: Drug: GDC-0853 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Adverse Events (AEs)
An Adverse Event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
Measured: Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months)
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 52
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Measured: Week 52
Secondary outcomes (25)
Percentage of Participants Achieving ACR50 Response up to Week 12
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Measured: Weeks 4, 8 and 12
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate]
Measured: Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Measured: Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 CRP)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.
Measured: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 CRP)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.
Measured: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 ESR)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.
Measured: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 ESR)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score < 2.6.
Measured: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants With Remission Based on Disease Activity Score Based on 28-Joints Count (DAS28)
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.
Measured: Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants With Low Disease Activity (LDA) Based on DAS28
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2
Measured: Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants With ACR/EULAR Remission
Assessed according to the Boolean based definition (tender joint count =<1, swollen joint count =<1, C-reactive Protein (CRP) =<1, and patient global assessment =<1)
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Simplified Disease Activity Index (SDAI)
Simplified Disease Activity Index (SDAI) is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PhGA (based on 0-10 cm VAS, where 0 = no disease activity and 10 = worst disease activity), and CRP. SDAI total score ranges from 0 (no disease activity) to 86 (maximal disease activity), where higher scores represents higher disease activity. The SDAI =< 3.3 indicates disease remission, > 3.4 to 11 indicates low disease activity, > 11 to 26 indicates moderate disease activity, and > 26 indicates high disease activity
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Clinical Disease Activity Index (CDAI)
CDAI was derived as the sum of the following: tender joint count (TJC), swollen joint count (SJC), participant global assessment (PGA) of disease activity, and physician assessment of disease activity. TJC and SJC were taken as the number of tender and swollen joints, respectively, out of 28 assessed joints. PGA and physician assessment of disease activity were scored 0-100 millimeters (mm) and rounded to the nearest centimeter (cm) on a visual analog scale (VAS), where higher scores indicate greater perceived disease activity. The total CDAI score range was 0-76, where higher scores indicate increased disease activity. Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest. Negative values indicate improvement/reduction in RA disease activity.
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Tender/Painful Joint Count Based on 68 Joints
Tender Joint Count: a total of 68 joints will be assessed for tenderness. Each joint is assessed for the presence/absence of tenderness. 68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Swollen Joint Count Based on 66 Joints
Swollen Joint Count: a total of 66 joints will be assessed for swelling. Each joint is assessed for the presence/absence of swelling. 66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Patient's Assessment of Arthritis Pain, Using Visual Analog Scale (VAS) Score
Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Patient's Global Assessment of Arthritis, Using VAS Score
Participant-assessed arthritis pain was scored on a 100-mm VAS, where the distance from 0 mm represented the participant's self evaluation of arthritis pain (0 mm=none; 100 mm=very severe). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change indicated a decrease in participant-assessed arthritis pain.
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Physician's Global Assessment of Arthritis, Using VAS Score
Physician's assessment of participant's disease activity was scored on a 100-mm VAS, where the distance from 0 mm represented the physician's assessment of the participant's disease activity (0 mm=very good; 100 mm=very poor). Change from baseline at a particular time point was calculated among patients with data available at both baseline and the time point of interest, where negative change from baseline indicated an improvement in physician-assessed disease activity.
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in C-Reactive Protein (CRP) Levels
C-reactive protein is a biological marker of inflammation and is measured in milligrams per decilitre (mg/dL)
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
The Stanford Health Assessment Questionnaire disability index is a patient-reported outcome used to assess difficulty in performing activities of daily living. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities.
To respond to each question, a four-level response with higher scores showing larger functional limitations, was chosen. Scoring is as follows with respect to performance of participant's everyday activities: 0 (equals)=without difficulties; 1= with some difficulties; 2=with great difficulties; and 3=unable to perform these actions at all. The composite HAQ-DI score is the mean of the eight domain scores and the score ranges from 0 (no functional impairment) to 3 (maximum functional impairment). A negative change from baseline indicates improvement.
Measured: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components
The 36-Item Short Form Health Survey (SF-36v2) is a questionnaire used to assess functional health and well-being and consists of eight domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health.
The SF-36v2 is summarized into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The PCS and MCS scores range from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from baseline indicates improvement.
Measured: Weeks 12, 24 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
The FACIT-Fatigue Scale consists of 13 items designed to measure the degree of fatigue experienced by the patient in the previous 7 days. For each question, there are five possible responses: 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much).
A total fatigue score is calculated by summing all items, and possible total scores range from 0 (maximum fatigue) to 52 (no fatigue). A positive change from baseline indicates an improvement in the patient's fatigue (less fatigue).
Measured: Weeks 12, 24 and 52
Area Under the Concentration Time Curve (AUC) of GDC-0853 at Steady State (AUC,ss)
Population PK model estimated AUC of GDC-0853 at steady-state. AUC was measured in Nanograms (ng) per millilitre(mL)*hour (hr).
Measured: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Minimum Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss)
Population PK model estimated minimal plasma concentration (Ctrough) of GDC-0853 at steady-state (ss).
Measured: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Plasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss)
Population PK model estimated plasma decay half life of GDC-0853 at steady-state.
Measured: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Apparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss)
Population PK model estimated apparent oral clearance of GDC-0853 at steady-state.
Measured: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Dec 2016 (estimated)
- Study start30 Nov 2016
- Primary completion17 Jul 2019
- Study completion17 Jul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by Genentech, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 496 participants (actual)
Sponsor and investigators
- Lead sponsor
- Genentech, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02983227
- Sponsor's protocol ID
- GA30067
- Other IDs
- 2016-000498-19, 2016
- Status last verified
- Jul 2020
- First submitted
- 29 Nov 2016
- Last updated
- 3 Aug 2020
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Aug 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis
- ClinicalTrials.gov ID
- NCT02983227
- Acronym / sponsor ID
- GA30067
- Conditions
- Rheumatoid Arthritis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 496 participants (actual)
- Lead sponsor
- Genentech, Inc.Industry (pharma, biotech, devices)
- Study start
- 30 Nov 2016 (actual)
- Primary completion
- 17 Jul 2019 (actual)
- Study completion
- 17 Jul 2019 (actual)
- First posted
- 6 Dec 2016 (estimated)
- Results
- Posted 3 Aug 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Eligible participants from Study GA29350 who elect to participate will receive treatment with GDC-0853 twice daily (BID) in an open-label fashion for 52 weeks, followed by a safety follow-up period of 8 weeks.
Study design
- Primary purpose
- Treatment
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| GDC-0853 (200mg BID) Cohort 1 | Experimental | Drug: GDC-0853Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 1 of Study GA29350. Cohort 1 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to previous methotrexate (MTX) therapy and then randomized to 12 weeks of GDC-0853 (50 mg daily, 150 mg daily, or 200 mg BID), adalimumab, or placebo. |
| GDC-0853 (200mg BID) Cohort 2 | Experimental | Drug: GDC-0853Participants received GDC-0853 orally twice daily (BID) for 52 weeks, after completing 12 weeks in Cohort 2 of Study GA29350. Cohort 2 participants in GA29350 were enrolled with moderate to severe active Rheumatoid Arthritis (RA) and an inadequate response to one or two tumor necrosis factor (TNF) inhibitors and methotrexate (MTX) therapy, and then randomized to 12 weeks of GDC-0853 (200 mg BID) or placebo. |
Who may qualify
- Ages
- 18 to 76 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Completion of treatment as specified in Study GA29350, including completion of the Day 84 study visit assessments
- Acceptable safety and tolerability during Study GA29350 as determined by the investigator or Medical Monitor
- Have not received any prohibited medications in Study GA29350
- While taking methotrexate, must be willing to receive oral folic acid (at least 5 milligrams per week [mg/week])
- If receiving oral corticosteroids (less than or equal to [</=] 10 milligrams per day [mg/day] prednisone or equivalent) and/or non-steroidal anti-inflammatory drugs, doses have remained stable for the duration of Study GA29350
Key exclusion criteria (9 listed)
- Met protocol defined treatment stopping criteria during Study GA29350
- Treatment with any investigational agent (i.e., other than study drug) or live/attenuated vaccine or any other prohibited medication during Study GA29350 or since the last administration of study drug in Study GA29350
- In the opinion of the investigator, any new (since initially enrolling in the Phase II Study GA29350), significant, uncontrolled comorbidity that would increase the risk to the participant in Study GA30067
- Pregnant or lactating, or intending to become pregnant during the study
- Participants who experienced a de novo or reactivated serious viral infection such as hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) during the Phase II Study GA29350
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GDC-0853Also: RO7010939GDC-0853 was administered orally at a dose of 200mg, as per the dosing schedules described above. | Drug | GDC-0853 (200mg BID) Cohort 1, GDC-0853 (200mg BID) Cohort 2 |
Primary outcome
Percentage of Participants With Adverse Events (AEs)
Time frame: Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months)
An Adverse Event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 52
Time frame: Week 52
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
25 secondary outcomes
Percentage of Participants Achieving ACR50 Response up to Week 12
Time frame: Weeks 4, 8 and 12
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 CRP)
Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (4 Variables) (DAS28-4 CRP)
Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (3 Variables) (DAS28-3 ESR)
Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Disease Activity Score Based on 28-Joints Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 ESR)
Time frame: Baseline, Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants With Remission Based on Disease Activity Score Based on 28-Joints Count (DAS28)
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants With Low Disease Activity (LDA) Based on DAS28
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Percentage of Participants With ACR/EULAR Remission
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Simplified Disease Activity Index (SDAI)
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Clinical Disease Activity Index (CDAI)
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Tender/Painful Joint Count Based on 68 Joints
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Swollen Joint Count Based on 66 Joints
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Patient's Assessment of Arthritis Pain, Using Visual Analog Scale (VAS) Score
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Patient's Global Assessment of Arthritis, Using VAS Score
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Physician's Global Assessment of Arthritis, Using VAS Score
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in C-Reactive Protein (CRP) Levels
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
Time frame: Weeks 4, 8, 12, 24, 36 and 52
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Version 2.0 (V2) Scores for Physical and Mental Components
Time frame: Weeks 12, 24 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
Time frame: Weeks 12, 24 and 52
Area Under the Concentration Time Curve (AUC) of GDC-0853 at Steady State (AUC,ss)
Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Minimum Plasma Concentration of GDC-0853 at Steady State (Ctrough,ss)
Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Plasma Decay Half-Life of GDC-0853 at Steady State (t1/2,ss)
Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Apparent Oral Clearance of GDC-0853 at Steady State (CL/F,ss)
Time frame: Pre-dose (0 hour) on Weeks 0 (Day 1), 4, 12, 24, 36, and 52/early termination
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Aug 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Rheumatoid Arthritis
RecruitingPhase 1
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Not yet recruiting
Effects of Paraffin Wax Therapy and Dry Cupping on Pain and Wrist Function in Patients With Rheumatoid Arthritis
Rheumatic Arthritis
RecruitingPhase 2
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Sjogren's Syndrome
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingPhase 1/2
A Study of AZD0120 in Autoimmune Diseases
Systemic Sclerosis, Idiopathic Inflammatory Myopathies
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
104 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing GDC-0853 in people with Rheumatoid Arthritis, run by Genentech, Inc. at 104 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Aug 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 104 sites in Ukraine, Russia, United States, Argentina, Bulgaria and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Aug 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Adverse Events (AEs) (time frame: Day 1 up until 8 weeks after the last dose of study drug (up to 1 year, 2 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2020.